Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. (LXEO) priced its initial public offering on Nov 6, 2023 at $11.00 per share, below its $13.00–$15.00 range, raising $100M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $276.9M. J.P. Morgan was lead-left underwriter, joined by Leerink Partners, Stifel and RBC Capital Markets and others. Paul Hastings advised the underwriters.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company that began substantive operations in 2020 and develops gene therapy candidates aimed at the underlying genetic cause of the diseases it targets.

Status

IPO

Ticker

LXEO

Exchange

Nasdaq Global Market

Priced

Nov 6, 2023

IPO price

$11.00

Price range

$13.00–$15.00

Raised

$100M

Market cap at IPO price

$276.9M

First filed

Sep 29, 2023

Underwriters

J.P. Morgan, Leerink Partners, Stifel, RBC Capital Markets and Chardan

Underwriters' counsel

Paul Hastings

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.